![]() |
|
|
Vol. 292, Issue 1, 381-386, January 2000
The Cardiovascular Research Group, Departments of Medicine and
Pathology, The University of Calgary, Calgary, Alberta, Canada
This study tested the hypothesis that combination ion channel blockers
of the transient outward current (Ito) and
the rapid component of the delayed rectifying current
(IKr) would produce greater prolongation of
the ventricular action potential duration (APD) and increased
dispersion of the APD in hypertrophied hearts compared with control
hearts. Isolated rabbit hearts were studied 48 ± 5 days
postabdominal aortic banding. Left ventricular endocardial and
epicardial APDs were significantly greater at baseline in the
hypertrophied group than in controls (P < .05).
The magnitude of APD prolongation induced by the
Ito blocker 4-aminopyridine (4-AP) and
combination 4-AP and the IKr blocker
dofetilide was greater in the hypertrophied hearts than in the normal
hearts (P < .01). Mean APD dispersion was
significantly greater in the hypertrophied group than in the control
hearts at baseline (P < .05). 4-AP increased APD
dispersion by a similar magnitude in the hypertrophied hearts (10 ± 10 ms) and the control hearts (8 ± 8 ms, P = NS), whereas the combination 4-AP and dofetilide increased APD
dispersion by a greater magnitude in the hypertrophied hearts (41 ± 28 ms) than the control hearts (21 ± 11 ms,
P < .05). Ventricular fibrillation occurred
spontaneously in four hypertrophied hearts (40%) during combination
drug perfusion and in none of the control hearts (P < .05). Thus, combination Ito and
IKr blockers cause greater prolongation APD
and increased APD dispersion in left ventricular hypertrophy, and this
is associated with the development of ventricular fibrillation.
This article has been cited by other articles:
![]() |
X.-S. Liu, M. Jiang, M. Zhang, D. Tang, H. F. Clemo, R. S. D. Higgins, and G.-N. Tseng Electrical remodeling in a canine model of ischemic cardiomyopathy Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H560 - H571. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Gillis, K. M. Kavanagh, H. J. Mathison, J. R. Somers, S. Zhan, and H. J. Duff Heart block in mice overexpressing calcineurin but not NF-AT3 Cardiovasc Res, December 1, 2004; 64(3): 488 - 495. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Oikarinen, M. S. Nieminen, M. Viitasalo, L. Toivonen, S. Jern, B. Dahlof, R. B. Devereux, P. M. Okin, and for the LIFE Study Investigators QRS Duration and QT Interval Predict Mortality in Hypertensive Patients With Left Ventricular Hypertrophy: The Losartan Intervention for Endpoint Reduction in Hypertension Study Hypertension, May 1, 2004; 43(5): 1029 - 1034. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-X. Yan, S. J. Rials, Y. Wu, T. Liu, X. Xu, R. A. Marinchak, and P. R. Kowey Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H1968 - H1975. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wolk Arrhythmogenic mechanisms in left ventricular hypertrophy Europace, January 1, 2000; 2(3): 216 - 223. [Abstract] [PDF] |
||||